GATA3
- Known as:
- GATA3
- Catalog number:
- GTX109654
- Product Quantity:
- 100 µg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- GATA3
Related genes to: GATA3
- Gene:
- GATA3 NIH gene
- Name:
- GATA binding protein 3
- Previous symbol:
- -
- Synonyms:
- HDR
- Chromosome:
- 10p14
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-03
- Date modifiied:
- 2016-10-05
Related products to: GATA3
Related articles to: GATA3
- Lung structural cells contribute to allergic airway inflammation; however, the lung cell type that mounts the most vigorous early transcriptional response to allergen exposure remains unclear. In this study, we used single-nucleus RNA sequencing to define early allergen-induced transcriptional programs across major lung structural cell populations. - Source: PubMed
Publication date: 2026/04/21
Govindhan AnnamalaiSur AakashHosoki KoaSur Sanjiv - Signet ring cell carcinoma (SRCC) of the breast is an exceptionally rare subtype accounting for only 0.04% to 2.7% of all breast cancers. Pure SRCC is characterized by the presence of >90% signet ring cells and exhibits an aggressive clinical profile often associated with higher histologic grade, lympho-vascular invasion, hormone receptor positivity, and low HER2 expression. Differentiating primary mammary SRCC from metastases from gastrointestinal primary, especially in elderly patients with bilateral presentations is of prime importance. Immunohistochemistry plays a crucial role in this regard with primary breast SRCCs displaying ER, GATA3 and CK7 positivity and CK20 and CDX2 negativity. We report a case of bilateral signet ring cell carcinoma breast in an 82 year-old female. This case highlights the significance of recognising SRCC breast as a distinct pathological entity and thorough evaluation in case of bilateral presentation as it is exceptionally uncommon and poses diagnostic and therapeutic challenges. - Source: PubMed
Publication date: 2026/02/25
Dhull GarimaPujani MuktaChauhan VarshaDey AnirunaGarg NehaRaghav NehaMadaan SonaliKaul Kartik - The coexistence of benign mesonephric-like proliferation (MLP), mesonephric-like hyperplasia (MLH), and mesonephric-like adenocarcinoma (MLA) with ovarian mucinous cystadenoma or mucinous borderline tumor (MBT) has been previously reported; however, this phenomenon is exceedingly rare, and understanding of the pathology and biology remains limited. Here we report additional cases, with an emphasis on expanded observations and novel pathologic features. This series included 9 cases: (1) 2 cases of mixed MLA and endometrioid adenocarcinoma associated with cystic mucinous neoplasm of lower gastrointestinal (GI) type (case 1) or mucinous cystadenoma (case 2); (2) 1 case of MLA associated with MBT and mucinous adenocarcinoma (case 3); (3) 4 cases of MLA associated with MBT (cases 4 and 5) or mucinous cystadenoma (cases 6 and 7); and (4) 2 cases of MLP/MLH associated with MBT (cases 8 and 9). All mesonephric-like lesions were diffusely positive for PAX8 and either diffusely (7 cases) or focally (2 cases) positive for GATA3. Focal TTF-1 expression was observed in 4 cases (4/9, 44.4%). All mucinous tumors, except for case 1, showed either focal (4 cases) or diffuse (4 cases) PAX8 positivity. Molecular analysis in case 1 revealed a common KRAS p.G12A driver mutation in all 3 tumor components (MLA, endometrioid adenocarcinoma, and mucinous tumor), indicating clonal relatedness. In contrast, pathogenic somatic mutations in ARID1A, DNMT3A, PIK3CA, and TET2 were detected only in the MLA and endometrioid adenocarcinoma, but not in the mucinous tumor component, suggesting lineage-specific differentiation. Notably, case 1 represents the first reported example of a mesonephric-like lesion associated with a mucinous tumor exhibiting lower GI morphology and immunophenotype. Case 3 represents the first case with mucinous adenocarcinoma in this scenario. Case 9 represents the first reported instance in which both ovaries were independently involved by MLP/MLH and MBT. The presence of benign MLP/MLH alongside MLA suggests that the former may represent noncancerous precursor lesions with the potential to develop into MLA; they may represent benign (MLP) or borderline (MLH) mesonephric-like lesions. Whether mesonephric-like lesions serve as precursors of ovarian mucinous tumors remains debated, but their coexistence in the ovary, as documented in 20 cases to date (including previously published cases and the current series), may represent a unique biological process and provide an ideal model for investigating mechanisms of transdifferentiation and tumorigenesis. - Source: PubMed
Publication date: 2026/05/27
Smith ColtonDudley JonathanSavage JohannaVan de Vijver KoenHong LiuSong WeihuaKir GözdeKearns KaterinaShakiba DelaramAdamson Kathi HSmith Saron AWang YunLiu MeiLiu AijunVang RussellMcCluggage W GlennXing Deyin - Asthma represents a chronic inflammatory condition of the respiratory tract, where long-term bronchial inflammation serves as a primary driver of progressive airway remodeling. This complex pathology emerges from the intricate synergy between host genetic susceptibility and diverse environmental triggers, ultimately impairing pulmonary function. At the cellular level, asthmatic responses are orchestrated by a dynamic crosstalk among various immune and structural populations, including airway epithelial cells, T-lymphocytes, eosinophils, and mast cells, which collectively perpetuate the inflammatory milieu. Although inhaled corticosteroids are the conventional cornerstone of therapy, their clinical application is frequently hindered by potential systemic toxicity and the emergence of steroid-resistant phenotypes. Consequently, botanical extracts derived from both aerial and underground plant organs have gained attention as versatile multi-target candidates capable of modulating the multifaceted pathophysiological networks of asthma. This scoping review critically synthesizes the pharmacological efficacy of these plant-based interventions in regulating pivotal signaling cascades, such as MAPK, NF-κB, STAT3/6, and GATA3. Based on a systematic literature search covering the period from 2005 to 2025, this study provides a focused quantitative analysis of preclinical literature from the last decade (2016-2025) to evaluate the in vitro and in vivo models employed to validate these therapeutic effects. The assessment reveals that the vast majority of current research continues to rely on crude botanical preparations, with only a limited subset of studies utilizing enriched fractions or fully characterized isolated compounds. This predominance of unrefined extracts underscores a significant gap in chemical standardization and highlights the necessity for more rigorous mechanistic validation. Ultimately, this paper outlines strategic pathways for translating preclinical findings into clinical practice, offering a robust framework for the development of standardized plant-derived interventions in asthma management. - Source: PubMed
Publication date: 2026/05/18
Lee Jae-WonJeon Chang HyeonPark Soo-JinLee Hee JaeRyu Hyung WonLee Su Ui - Vulvar squamous cell carcinoma (VSCC) and its precursor lesions are relatively rare malignancies of the gynecologic tract. In recent years, international organizations and pathologic reporting guidelines endorse the subdivision of VSCC into human papillomavirus (HPV)-associated and HPV-independent types. There is also growing evidence for the further separation of HPV-independent into p53 abnormal and p53 wild-type cancers. Although the diagnosis and subclassification of VSCC is often straightforward, using immunohistochemical markers such as p16 and p53 as surrogate markers for high-risk HPV infection and mutation respectively, rare and unusual scenarios exist that can complicate VSCC classification. Herein we discuss these challenging scenarios in VSCC classification, as well as emerging VSCC prognostic biomarkers such as cyclin D1. In addition, the pathologic diagnosis of VSCC precursor lesions, particularly those of HPV-independent type, are frequently challenging to distinguish from benign conditions of the vulva. We discuss the recent literature describing the added diagnostic value of immunohistochemical biomarkers p53, CK17, CK13, SOX2, GATA3, GLUT1 and others, which may be particularly helpful when morphology is inconclusive. It is anticipated that with improved VSCC classification and precursor recognition, avenues for more tailored therapeutic strategies and earlier therapeutic intervention can be achieved. - Source: PubMed
Publication date: 2026/05/08
Alsolami SomayahJi JenniferHoang Lynn